Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

India's health biotech sector at a crossroads

Nature Biotechnology volume 25, pages 403–417 (2007)Cite this article

India's home-grown biotech companies must strike a balance between domestic and international markets.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kumar, N.K. et al. Indian biotechnology—rapidly evolving and industry led. Nat. Biotechnol. 22 Suppl, DC31–DC36 (2004).

    Article  CAS  PubMed  Google Scholar 

  2. Thorsteinsdóttir, H., Quach, U., Martin, D., Daar, A. & Singer, P. Health biotechnology innovation in developing countries. Nat. Biotechnol. 22 Suppl, DC1–DC52 (2004).

    Google Scholar 

  3. UNDP Commission on Private Sector and Development. Unleashing Entrepreneurship: Making Business Work for the Poor. United Nations Development Program, New York, (2004).

  4. Kalorama Information. BioGeneric Pharmaceuticals for Future Expired Biologic Patents in The Market for Generic Biologics: Issues, Trends, and Market Potential, 2nd Edition (http://www.marketresearch.com, New York, 2005).

  5. Palnitkar, U. Growth of Indian biotech companies, in the context of the international biotechnology industry. J. Commer. Biotechnol. 11, 146–154 (2005).

    Article  Google Scholar 

  6. Dhawan, J., Gokhale, R.S. & Verma, I.M. Bioscience in India: times are changing. Cell 123, 743–745 (2005).

  7. Mayor, S. Coming home. Nature 436, 488–489 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Wilkie, D. India wants to be your biotech source; a greater respect for intellectual property could boost India's ability to compete in 2005. The Scientist October 25, 2004) pp. 51–53.

    Google Scholar 

  9. De Rond, M. in Strategic Alliances as Social Facts: Business, Biotechnology, and Intellectual History (Cambridge University Press, Cambridge, UK, 2003).

    Book  Google Scholar 

  10. Bleed, D. et al. Global Tuberculosis Control—Surveillance, Planning, Financing. India: Country Profile. (World Health Organization Geneva, 2006). http://www.who.int/tb/publications/global_report/2006/pdf/full_report.pdf

  11. World Health Organization. Malaria Situation in SEAR Countries. (WHO, Geneva, 2004). http://www.searo.who.int/en/section10/section21/section340_4021.htm

  12. The Joint United Nations Program on HIV/AIDS and World Health Organization. Asia Fact Sheet: UNAIDS Epidemic Update. (2005). http://data.unaids.org/pub/GlobalReport/2006/200605-FS_Asia_en.pdf

  13. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes. Diabetes Care 27, 1047–1053 (2004).

    Article  PubMed  Google Scholar 

  14. World Health Organization. Preventing Chronic Diseases; A Vital Investment (World Health Organization, Geneva, 2005). http://www.who.int/chp/chronic_disease_report/en/index.html

  15. Jayaraman, K.S. Biotech boom. Nature 436, 480–483 (2005).

    Article  CAS  PubMed  Google Scholar 

  16. BioSpectrum-ABLE. BioSpectrum-ABLE Survey 2005. in India Biotechnology Handbook 2006 (sponsored by Department of Biotechnology, Government of India, 2006).

Download references

Acknowledgements

We gratefully acknowledge Christopher Earl, Nirmal Kumar Ganguly, Charles Gardner, Mario Gobbo, Hannah Kettler, Nandini Kumar, Raghunath A. Mashelkar, Beatrice Seguin, Andrew Taylor, Wendy Taylor, Halla Thorsteinsdottir and Marsha Wulff for their valuable comments and assistance in shaping the study design. The McLaughlin-Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy (formerly the Canadian Program on Genomics and Global Health) is primarily supported by Genome Canada through the Ontario Genomics Institute and the Ontario Research and Development Challenge Fund, and the Bill and Melinda Gates Foundation. This study is also funded by the Rockefeller Foundation (New York) and BioVentures for Global Health (Washington, DC), and through in-kind contributions from Burrill & Company (San Francisco) and Wulff Capital (Dallas). Other matching partners are listed at http://www.geneticsethics.net. A.S.D. and P.A.S. are supported by the McLaughlin Centre for Molecular Medicine. P.A.S. is supported by a Canadian Institutes of Health Research Distinguished Investigator award.

Author information

Authors and Affiliations

  1. Sarah E. Frew, Rahim Rezaie, Monali Ray, Abdallah S. Daar and Peter A. Singer are at the McLaughlin-Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy, University Health Network/McLaughlin Centre for Molecular Medicine at University of Toronto, MaRS Centre, South Tower, Suite 406, 101 College Street, Toronto, Ontario, M5G 1L7, Canada. peter.singer@utoronto.ca,

    Sarah E Frew, Rahim Rezaie, Monali Ray, Abdallah S Daar & Peter A Singer

  2. Stephen M. Sammut is at Wharton Health Care Systems, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6218, USA and Burrill & Company, San Francisco, California, 94111 USA.,

    Stephen M Sammut

Authors
  1. Sarah E Frew
    View author publications

    Search author on:PubMed Google Scholar

  2. Rahim Rezaie
    View author publications

    Search author on:PubMed Google Scholar

  3. Stephen M Sammut
    View author publications

    Search author on:PubMed Google Scholar

  4. Monali Ray
    View author publications

    Search author on:PubMed Google Scholar

  5. Abdallah S Daar
    View author publications

    Search author on:PubMed Google Scholar

  6. Peter A Singer
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

S.M.S. is affiliated with Burrill amp; Co., an international biotechnology venture capital firm with activities in India. He does not have a direct economic stake in the firm's activities in India.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frew, S., Rezaie, R., Sammut, S. et al. India's health biotech sector at a crossroads. Nat Biotechnol 25, 403–417 (2007). https://doi.org/10.1038/nbt0407-403

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0407-403

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing